trending Market Intelligence /marketintelligence/en/news-insights/trending/m9mhp7on26udz0cw4upzaw2 content esgSubNav
In This List

Radius Health appoints chief medical officer

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Radius Health appoints chief medical officer

Waltham, Mass.-based biotechnology company Radius Health Inc. appointed Charles Morris as chief medical officer.

Morris was previously chief development officer at PsiOxus Therapeutics Ltd. He has also worked as the chief medical officer at Allos Therapeutics Inc., where he focused on the development of Folotyn in hematologic and solid tumors.

Jesper Hoiland, president and CEO of Radius Health, said that Morris' experience of late-stage drug trials and regulatory approvals will be vital during the phase 3 study of Elacestrant, or RAD1901, a treatment for breast cancer.

Radius Health develops hormone-based treatments for bone diseases and cancer.